The platelet function dose‐response to abciximab during percutaneous coronary revascularization is variable

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Catheterization and cardiovascular interventions

• Publication date

  2001-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ccd.1320PMID 11747189
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention: Results of the GOLD (AU-Assessing Ultegra) Multicenter Study

  2001cited by this paper
• Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention.

  1999cited by this paper
• Efficacy of Abciximab Induced Platelet Blockade Using a Rapid Point of Care Assay

  1999cited by this paper
• Rapid platelet-function assay: an automated and quantitative cartridge-based method.

  1999cited by this paper
• Randomised placebo-controlled and balloon-angioplasty- controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

  1998cited by this paper
• Monitoring platelet GP IIb/IIIa antagonist therapy.

  1998cited by this paper
• Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

  1998cited by this paper
• Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.

  1997cited by this paper
• Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.

  1997cited by this paper
• Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade.

  1997cited by this paper
• Monitoring platelet GP IIb/IIIa [corrected] antagonist therapy.

  1997cited by this paper
• Monitoring platelet GP IIb/IIIa [corrected] antagonist therapy.

  1997cited by this paper
• Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.

  1994cited by this paper
• Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

  1994cited by this paper
• Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein llb/llla in patients undergoing elective coronary angioplasty

  1993cited by this paper
• Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors.

  1989cited by this paper
• The platelet membrane glycoprotein IIb-IIIa complex.

  1988cited by this paper
• Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation.

  1988cited by this paper
• Sex-related differences in platelet aggregation: influence of the hematocrit.

  1980cited by this paper

• Comparative assessment of platelet GpIIb/IIIa receptor occupancy ratio with Eptifibatide/Tirofiban in patients presenting with ACS and undergoing PCI.

  2013cites this paper
• The use of the VerifyNow system to monitor antiplatelet therapy: A review of the current evidence

  2008cites this paper
• Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention.

  2006cites this paper
• Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS.

  2006cites this paper
• Glycoprotein IIb/IIIa Antagonists

  2003cites this paper
• Monitoring Glycoprotein IIb-IIIa Antagonists in Patients with Coronary Artery Disease/Monitoring von Glykoprotein IIb-IIIa-Antagonisten bei Patienten mit koronarer Herzerkrankung

  2002cites this paper